Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 20

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 20
---
 is highly and uniformly overexpressed in patients with recurrent/metastatic ACC 3 • B7 - H4 is also expressed in other adult and pediatric tumor types with high unmet need 4 • Emi - Le is a B7 - H4 - directed ADC, utilizing a target - optimized molecular design and a proprietary linker - payload ( Dolasynthen ) 5 • Measurable anti - tumor activity observed in patients living with ACC - 1 and a well - defined safety profile support accelerated clinical development 1,6 Emi - Le ( Emiltatug Ledadotin ) 1 Potential First - in - Class B7 - H4 - targeted ADC opportunity in ACC 1. Hamilton EP et al. 2025 ASCO Annual Meeting; 2. Adenoid Cystic Carcinoma Research Foundation; 3. Mota Siquera J et al 2024 Modern Pathology; 4 . Dawidowicz M et al 2024 Cancers ; 5. Fessler et al 2023 Mol Cancer Ther ; 6. Hamilton E et al 2025 ESMO Breast Cancer

Financial Overview & Transaction Details 9 Charles York Chief Operating Officer & Chief Financial Officer

Financial Overview And Transaction Details 10 Major EMA market includes France, Germany, Italy, Spain or the United Kingdom. Emi - Le, Emiltatug Ledadotin Purchase Price $25 per share Approximately $129 million in aggregate One Non - Tradeable Contingent Value Right (CVR) Up to $30.25 per share Approximately $156 million in aggregate Transaction funded with existing cash resources. Strong cash position and financial profile expected to advance Emi - Le through potential approval with no additional financing. Clinical Milestones - A development milestone related to an existing partnership agreement: $1.25 per share - Breakthrough Therapy Designation for ACC granted by FDA: $1.00 per share - Initiation of registrational trial for ACC: $4.00 per share Regulatory/Sales Milestones - Accelerated approval granted by FDA in ACC: $9.00 per share - 1st commercial sale in major EMA markets: $2.00 per share - 1st commercial sale in Japan: $1.00 per share - Annual net sales exceed $100mm by 2032: $2.00 per share - Annual net sales exceed $200mm by 2035: $4.00 per share - Annual net sales exceed $300mm